Literature DB >> 19424016

Hurdles to the induction of tolerogenic mixed chimerism.

Nina Pilat1, Christoph Klaus, Elisabeth Schwaiger, Thomas Wekerle.   

Abstract

To date, organ transplant patients have to deal with the numerous side effects of life-long dependence on immunosuppressive drugs, whereas at the same time these drugs fail to prevent chronic rejection in many cases. Finding ways to establish donor-specific immunological tolerance thus remains one of the major goals in transplantation medicine. Tolerance through mixed chimerism can be achieved in rodents and in humans by the transplantation of hematopoietic stem cells. Widespread clinical application of this tolerance approach is, however, prevented by the toxicities of current bone marrow transplantation protocols in humans. Cytotoxic recipient conditioning and the hazard of graft-versus-host disease are unacceptable risks for organ transplant recipients. However, considerable progress has been made toward nontoxic conditioning regimens in animal studies. Translation of these findings into large animal models and the clinical setting is expected to be an important step toward broad clinical application of the mixed chimerism approach in organ transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19424016     DOI: 10.1097/TP.0b013e3181a2b9cc

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  The role of natural killer T cells in costimulation blockade-based mixed chimerism.

Authors:  Patrick-Nikolaus Nierlich; Christoph Klaus; Sinda Bigenzahn; Nina Pilat; Zvonimir Koporc; Ines Pree; Ulrike Baranyi; Masaru Taniguchi; Ferdinand Muehlbacher; Thomas Wekerle
Journal:  Transpl Int       Date:  2010-11       Impact factor: 3.782

2.  Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning.

Authors:  Elisabeth Schwaiger; Christoph Klaus; Veerle Matheeussen; Ulrike Baranyi; Nina Pilat; Haley Ramsey; Stephan Korom; Ingrid De Meester; Thomas Wekerle
Journal:  Exp Hematol       Date:  2011-11-13       Impact factor: 3.084

3.  The Macrophage-depleting Agent Clodronate Promotes Durable Hematopoietic Chimerism and Donor-specific Skin Allograft Tolerance in Mice.

Authors:  Zhanzhuo Li; Xin Xu; Xingmin Feng; Philip M Murphy
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.